Sector
PharmaceuticalsOpen
₹7,421Prev. Close
₹7,392.15Turnover(Lac.)
₹1,252.02Day's High
₹7,421Day's Low
₹7,170.252 Week's High
₹8,13952 Week's Low
₹4,475Book Value
₹280.05Face Value
₹2Mkt Cap (₹ Cr.)
17,976.5P/E
137.08EPS
52.4Divi. Yield
0.33The company plans to launch Durvalumab in 120 mg/2.4 mL and 500 mg/10 mL solutions in India, pending statutory approvals.
The said indication is for the use of durvalumab in combination with chemotherapy as a neoadjuvant treatment.
Here are some of the stocks that may see significant price movement today: Punjab National Bank, NTPC, Power Grid, etc.
The plan to reduce the GST on these drugs aims to significantly reduce the overall cost of cancer treatment.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 706.92 | 583.69 | 506.39 | 451.17 |
Net Worth | 711.92 | 588.69 | 511.39 | 456.17 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 805.6 | 813.56 | 831.81 | 571 |
yoy growth (%) | -0.97 | -2.19 | 45.67 | 5.01 |
Raw materials | -311.96 | -294.95 | -305.23 | -181.09 |
As % of sales | 38.72 | 36.25 | 36.69 | 31.71 |
Employee costs | -230.21 | -219.54 | -216.7 | -153.53 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 83.04 | 127.09 | 113.97 | 43.8 |
Depreciation | -16.95 | -20.13 | -18.58 | -14.74 |
Tax paid | -21.44 | -33.79 | -41.76 | -17.89 |
Working capital | 57.86 | 101.15 | 103.65 | 52.76 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -0.97 | -2.19 | 45.67 | 5.01 |
Op profit growth | -36.38 | 12.23 | 160.74 | 25.31 |
EBIT growth | -34.47 | 11.35 | 162.8 | 23.38 |
Net profit growth | -33.97 | 29.2 | 178.69 | 29.22 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,887.55 | 162.64 | 4,52,670.53 | 237.82 | 0.72 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,817.95 | 93.02 | 1,54,512 | 430 | 0.51 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,510.35 | 30.73 | 1,22,039.52 | 1,055.94 | 0.86 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,339.65 | 75.14 | 1,12,925.71 | 469 | 0.84 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,662.4 | 26.98 | 1,11,144.22 | 1,417.2 | 0.6 | 5,823.9 | 1,458.55 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Independent Directo
Narayan K Seshadri
Non-Exec. & Independent Dir.
Revathy Ashok
Non-Exec. & Independent Dir.
Shilpa Divekar Nirula
Managing Director
Sanjeev Panchal
Non Executive Director
Hooi Bien Chuah
Non Executive Director
Sylvia Lorena Varela Ramon
Executive Director
Bhavana Agrawal
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Astrazeneca Pharma India Ltd
Summary
AstraZeneca Pharma India (APIL) was incorporated on July 11, 1979. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company. The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology.AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Companys issued and paid up equity share capital. Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company. AstraZeneca Pharmaceuticals AB Sweden. AstraZeneca Pharma India Limited (the Company) is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC, United Kingdom.The company expanded the installed capacity of Injectables during the year 2001 by 0.20 crores (Nos) and with this expansion the total capacity has been increased to 2.40 crores (Nos).The Companys marketing activities including medical services have been certified for ISO 9002. During 2001-02 the company has commiss
Read More
The Astrazeneca Pharma India Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹7190.6 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Astrazeneca Pharma India Ltd is ₹17976.50 Cr. as of 22 Oct ‘24
The PE and PB ratios of Astrazeneca Pharma India Ltd is 137.08 and 25.22 as of 22 Oct ‘24
The 52-week high/low is the highest and lowest price at which a Astrazeneca Pharma India Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Astrazeneca Pharma India Ltd is ₹4475 and ₹8139 as of 22 Oct ‘24
Astrazeneca Pharma India Ltd's CAGR for 5 Years at 24.42%, 3 Years at 33.24%, 1 Year at 56.99%, 6 Month at 37.12%, 3 Month at 15.10% and 1 Month at 6.56%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice